News

A look at the history of vaccines, our society's current standing in public health and vaccine preparedness, and what may come in the near future.

What role does new research play in combating public vaccination concerns?

Peter Hotez, MD, PhD, recently authored a paper proposing a federally directed but state-adaptive reopening that aims for acceptable national suppression by October 1.

IDSA, HIVMA request they be included in ongoing COVID-19 clinical trials.

A discussion on the process by which the FDA regulates vaccine candidates at a time when COVID-19 candidates are progressing.

Here is a compilation of the COVID-19 vaccine candidates that have achieved FDA Emergency Use Authorization, other approvals, and are in phases 1-3.

RedHill Biopharma has initiated a global phase 2/3 study in order to evaluate the use of opaganib in patients with severe COVID-19.

On Tuesday, Cain was said to be recovering, possibly reflecting the complex immune system stages of COVID-19 disease course.

Why reducing pandemic research and response to yes-or-no outcomes is harming public health.

People with travel links to China, Iran, and Italy may have accounted for nearly two-thirds of early COVID-19 cases in affected countries.

The method extracts SARS-CoV-2 RNA with the Mag-Bind Viral RNA Xpress Kit and the Hamilton MagEx STAR.

Dr. Adam Brufsky, an oncologist, compares viral and cancer immunity. Dr. Patrick Soon-Shiong connects the relation to COVID-19 vaccine research.

What should be anticipated in effectiveness and implication for the leading candidates.

Roche’s tocilizumab did not improve clinical status in hospitalized adult patients with severe COVID-19 associated pneumonia.

Infectious disease specialists explain how long term international cooperation with impacted societies can help to stop the cycle of Ebola outbreaks.

Nearly half of all the people living with HIV are over the age of 50, so age-related comorbidities are becoming a factor.

What happens if we don't get a COVID-19 vaccine? Patrick Soon-Shiong, MD, describes another potential route for research efforts, which could also supplement vaccine development.

One cardiologist speaks about what she witnessed in her NYC hospital including how the virus can be multi-organ and the development of COVID-19 diagnostic protocols.

A cohort assessment of New York-based deliveries from SARS-CoV-2 positive mothers showed no infants were infected nor symptomatic after 2 weeks.

A new modeling study reveals that transmission rates decline if people get their results early and quickly notify contacts of potential exposure.

Dr. Patrick Soon-Shiong and Dr. Adam Brufsky move on from the messenger RNA candidates to the adenovirus vaccines.

The federal agency gives approval for technology company’s test that supports unmonitored testing.

Dr. Patrick Soon-Shiong, Chairman and CEO of ImmunityBio, explains why T-cell immunity could be an important metric when evaluating experimental COVID-19 vaccines.

The randomized, placebo-controlled trial will be enrolling 30000 American adults to test the safety and efficacy of the codeveloped vaccine.

Researchers have identified which olfactory cell types are vulnerable to the virus.

FDA reissues LabCorp’s existing diagnostic test for EUA, which opens up testing protocol for anyone.

A round up of the week's infectious disease pipeline developments.

Weekly, we identify FDA product and drug recalls which have the potential to be clinically relevant.